Birth Defects Res A Clin Mol Teratol by O\u2019Leary, Leslie A. et al.
Methods for Surveillance of Fetal Alcohol Syndrome: The Fetal 
Alcohol Syndrome Surveillance Network II (FASSNetII) – 
Arizona, Colorado, New York, 2009 - 2014
Leslie A. O’Leary1,*, Linnette Ortiz2, April Montgomery3, Deborah J. Fox4, Christopher 
Cunniff2, Margaret Ruttenber3, April Breen5, Sydney Pettygrove2, Don Klumb6, Charlotte 
Druschel4, Jaime Frías1,7, Luther K. Robinson8, Jacquelyn Bertrand1, Kelly Ferrara2, 
Maureen Kelly2, Suzanne M. Gilboa1, and F. John Meaney2 for the FASSNetII9
1Centers for Disease Control and Prevention, National Center on Birth Defects and 
Developmental Disabilities, Atlanta, Georgia
2University of Arizona, Department of Pediatrics, Tucson, Arizona
3Colorado Department of Public Health and Environment, Colorado Responds to Children with 
Special Needs, Denver, Colorado
4New York State Department of Health, Bureau of Environmental & Occupational Epidemiology, 
Albany, New York
5New York State Department of Health, Congenital Malformations Registry, Buffalo, New York
6Sewall Child Development Center, Denver, Colorado
7 McKing Consulting Corporation, Fairfax, Virginia
8Women and Children’s Hospital of Buffalo, Buffalo, New York
Abstract
Surveillance of fetal alcohol syndrome (FAS) is important for monitoring the effects of prenatal 
alcohol exposure and describing the public health burden of this preventable disorder. Building on 
the infrastructure of the Fetal Alcohol Syndrome Surveillance Network (FASSNet, 1997-2002), in 
2009 the Centers for Disease Control and Prevention awarded five-year cooperative agreements to 
three states, Arizona, Colorado, and New York, to conduct population-based surveillance of FAS. 
The Fetal Alcohol Syndrome Surveillance Network II (FASSNetII, 2009-2014) developed a 
surveillance case definition based on three clinical criteria: characteristic facial features, central 
nervous system abnormalities, and growth deficiency. FASSNetII modified the FASSNet methods 
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in three important ways: 1) estimation of a period prevalence rather than birth prevalence; 2) 
surveillance of FAS among school-age children (ages 7-9 years) to better document the central 
nervous system abnormalities that are not apparent at birth or during infancy; and 3) 
implementation of an expert clinical review of abstracted data for probable and confirmed cases 
classified through a computerized algorithm. FASSNetII abstracted data from multiple sources 
including birth records, medical records from child development centers or other specialty clinics, 
and administrative databases such as hospital discharge and Medicaid. One challenge of 
FASSNetII was its limited access to non-medical records. Therefore, the FAS prevalence that 
could be estimated was that of the population identified through an encounter with the healthcare 
system. Clinical and public health programs that identify children affected by FAS provide critical 
information for targeting preventive, medical and educational services in this vulnerable 
population.
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Birth defects; clinical review; developmental disabilities; fetal alcohol syndrome; population-
based surveillance
INTRODUCTION
Prenatal exposure to alcohol causes a range of abnormal clinical outcomes referred to as 
fetal alcohol spectrum disorders (FASDs); the most involved manifestation of which is fetal 
alcohol syndrome (FAS). Diagnostic features of FAS include facial dysmorphology, central 
nervous system (CNS) abnormalities, and growth deficiency (Jones et al., 1973). Individuals 
with FAS have physical and cognitive disabilities requiring costly, lifelong care. A recent 
report revealed that the average annual medical expenditure for children with FAS is nine 
times greater than for children without FAS (Amendah et al., 2011). Identifying children 
with FAS and providing appropriate interventions are key steps toward monitoring the 
impact and burden of this condition and improving the quality of life for these individuals 
and their families (Olson and Montague, 2011).
Public health surveillance of FAS presents unique challenges compared to other birth 
defects and developmental disabilities. In particular, because both physical and 
neurodevelopmental issues are included in the diagnostic criteria, multiple data sources are 
usually required to satisfy the case definition. Also, alcohol use during pregnancy might not 
be documented in records. In situations of maternal addiction, children affected by prenatal 
alcohol exposure might not reside with their birth mother complicating record finding. 
Finally, although some physical features of FAS are present at birth or in infancy, many of 
the CNS abnormalities associated with FAS do not manifest until the late preschool or early 
school years.
Despite these challenges, efforts to quantify the number of children with FAS continue. 
Reported prevalence of FAS worldwide ranges from 0.1 to 120 per 1,000 children (May et 
al., 2009) depending on the study population. Within the United States the prevalence of 
FAS, as reported by the Centers for Disease Control and Prevention (CDC), ranges from 0.1 
to 1.5 cases per 1,000 births (CDC, 1993; CDC, 1995; CDC, 1997; CDC, 2002). May et al. 
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(2009) reported a range of 2 to 7 per 1,000 cases in various racial and socioeconomic 
populations in the United States. The variation in prevalence is likely the result of 
differences in case definition and ascertainment methods, but could also reflect regional 
differences in the prevalence of prenatal alcohol exposure.
In 1997, the CDC awarded five-year cooperative agreements to Alaska, Arizona, Colorado, 
New York, and Wisconsin, to establish or enhance population-based surveillance of FAS 
among infants and young children. These states became known as the Fetal Alcohol 
Syndrome Surveillance Network (FASSNet). FASSNet developed a multiple-source 
methodology for conducting surveillance of FAS through review of medical and clinical 
records (Hymbaugh et al., 2002) and in collaboration with CDC developed a surveillance 
case definition based on the diagnostic criteria presented in the 1996 Institute of Medicine 
report on FAS (IOM, 1996).
Building on the infrastructure of FASSNet, in 2009 CDC awarded five-year cooperative 
agreements to Arizona, Colorado, and New York, referred to as the Fetal Alcohol Syndrome 
Surveillance Network II (FASSNetII), to conduct population-based surveillance of FAS in 
children ages seven to nine years. The older age cohort was selected to detect CNS 
abnormalities that are not apparent at birth or during infancy. In addition, a clinical review 
component was developed and implemented as part of the surveillance methodology. In this 
manuscript we describe the methodology used by FASSNetII.
METHODS
Population
The FASSNetII study population included children ages seven, eight, and nine years (birth 
years 2001, 2002 and 2003) who resided within the catchment areas of the three sites, 
Arizona, Colorado, and New York, in the year 2010. Arizona ascertained cases statewide, 
whereas Colorado selected a seven county area (metropolitan Denver: Adams, Arapaho, 
Boulder, Broomfield, Denver, Douglas, and Jefferson counties) and New York selected nine 
western counties (Allegany, Cattaraugus, Chautauqua, Erie, Genesee, Monroe, Niagara, 
Orleans, Wyoming). Since residency can be difficult to determine for children with FAS 
because of frequent placement in foster care or being under the supervision of Child 
Protective Services, a residency criteria protocol was implemented. Generally, if a child’s 
address within the catchment area for the study year could not be confirmed, but an address 
within the catchment area was identified for the year prior to the study year (2009) and the 
year after the study year (2011) then residency during 2010 was assumed to be within the 
catchment area.
Data Sources and Case-finding Procedures
FASSNetII used a standardized methodology that relied on both passive reporting of cases 
and active review of records from a variety of sources. In New York, FAS is a reportable 
condition by legislation and in Colorado, by board of health regulations. Reporting of FAS 
is not mandated in Arizona.
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To identify potential cases of FAS, sites used their state birth defects monitoring program, 
which included access to vital records, hospital discharge data, and selected administrative 
data sets. In addition, other surveillance systems (e.g., autism and other developmental 
disabilities) were used to identify children who might have FAS. Additional sources 
included Medicaid and health maintenance organization databases, as well as data from the 
juvenile justice system. Genetic, developmental and specialty clinics were contacted and 
asked to identify children evaluated for suspected or confirmed FAS, alcohol-related 
neurodevelopmental disorders (ARND) or prenatal alcohol exposure. Private physicians also 
were contacted to request reports of children with FAS, but no children with FAS were 
identified from this source.
Computer queries of International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes were used at several sources to identify children who might 
have FAS. The ICD-9-CM code 760.71 (alcohol affecting fetus or newborn via placenta or 
breast milk) was the code most often used, either alone or in combination with other codes 
such as ICD-9-CM codes 315 (specific delays in development), 317 (intellectual disability – 
mild), 318 (intellectual disability – other specified), 742 (other congenital anomalies of the 
nervous system), 764 (slow fetal growth and fetal malnutrition), 765 (disorders relating to 
short gestation and low birth weight) and 783 (symptoms concerning nutrition metabolism 
and development).
Once identified, records of children suspected of having FAS were screened to determine if 
they met the age and residency requirements before records were requested or data were 
abstracted. All possible data sources were pursued until the surveillance case definition was 
met or sources were exhausted.
Surveillance Case Definition
The surveillance case definition for FASSNetII (Table 1) used the same general criteria as 
FASSNet (Hymbaugh et al., 2002). These criteria were operationalized from the 
recommendations of the 1996 Institute of Medicine report on FAS (IOM, 1996) and 
included prenatal or postnatal growth deficiency, CNS abnormalities, and characteristic 
facial features. Since prenatal alcohol exposure is necessary to cause FAS, maternal alcohol 
use was included in the surveillance case definition and abstracted when available, but due 
to difficulty in obtaining documentation of this information, it was not required to meet the 
surveillance case definition.
Growth Deficiency—Growth deficiency was defined as weight, height/length, or weight 
for height/length at or below the 10th centile at any time from birth to the most recently 
abstracted record based on standard growth curves for intrauterine and postnatal growth 
(Kuczmarski et al., 2002; Alexander et al., 1996; Lubchenco et al., 1966). Postnatal 
measures were corrected for gestational age up to 24 months if the recorded gestational age 
was <37 weeks. Birth measures were corrected for gestational age if the recorded gestational 
age at birth was <40 weeks.
CNS Abnormalities—CNS abnormalities included small head circumference and/or CNS 
dysfunction diagnosed by a qualified examiner. Small head circumference was defined as a 
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measurement at or below the 10th centile at any time from birth to the most recently 
abstracted record and was assessed from standard curves of head circumference (Rollins et 
al., 2010; Lubchenco et al., 1966).
Qualifying criteria for CNS dysfunction included (1) a diagnosis of developmental delay if 
recorded in the medical record by a qualifying examiner or based on standardized testing 
results more than one standard deviation below the mean in at least two of the following 
developmental domains: language, cognitive/intellectual, adaptive functioning, social/
emotional/behavioral, executive functioning, memory, attention, academic motor and global/
general; (2) a standardized measure of intelligence falling at or greater than two standard 
deviations below the mean or a diagnosis of intellectual disability recorded in the medical 
record by a qualified examiner; and/or (3) a diagnosis of attention deficit disorder or 
attention deficit hyperactivity disorder (ADHD) recorded in the medical record by a 
qualified examiner. A qualified examiner was defined as an examiner with the appropriate 
license or degree and deemed qualified in the field of interest.
Facial Features—Short palpebral fissures, abnormally smooth philtrum, and thin upper 
lip are the most discriminating facial features of FAS. The case definition criterion for these 
facial anomalies was met through either (1) a qualitative statement from a qualified 
examiner that the child had facial features consistent with a diagnosis of FAS, or (2) 
documentation by a qualified examiner of at least two of the three characteristic facial 
features of FAS (i.e., short palpebral fissures, smooth philtrum and thin upper lip). The short 
palpebral fissure criterion was met by either a qualitative statement from a qualified 
examiner or by an objective measure recorded in the medical record that was compared to a 
standard used for palpebral fissure length (Thomas et al., 1987). Likewise, the lip and 
philtrum criteria were met by either a qualitative statement or by documentation of a level 
four or five lip/philtrum appearance according to the criteria developed by Astley and 
Clarren (1995).
Case Classification
Documentation of the specific features characteristic of FAS formed the basis of case 
classification as confirmed, probable, or not FAS. An individual was considered positive for 
one of these features if a qualified examiner documented the feature in any of the abstracted 
records. Confirmed FAS was defined as documentation of facial features, CNS 
abnormalities and growth deficiency; probable FAS was defined as documentation of facial 
features and either CNS abnormalities or growth deficiency (Table 1). In FASSNet, case 
classification was done by a computer-generated algorithm, while in FASSNetII case 
classification was accomplished by the computer-generated algorithm as well as a clinical 
review of abstracted data for a subset of potential cases.
Case Classification by Computer Algorithm—A computer-generated algorithm 
examined all characteristic features of FAS across all abstracted records and used those 
features to assign case status. The algorithm employed the most inclusive criteria for 
confirmed and probable FAS, since it recognized a feature to be present if it had ever been 
documented as present, regardless of whether that feature was documented as not present by 
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another qualified examiner in another record. The algorithm did not distinguish between 
qualified examiners who might have different levels of expertise to judge the phenotypic 
facial features, so observations of a pediatrician, developmental pediatrician and a clinical 
geneticist or dysmorphologist each carried equal weight. The algorithm also did not 
distinguish between examiners such as developmental pediatricians, family practitioners, or 
pediatricians who have different levels of expertise to judge developmental disability. In 
addition, documentation of a characteristic feature of FAS at any age was acceptable.
Case Classification by Clinical Review—To conduct case classification in more depth 
than was possible through an algorithm-based process alone, FASSNetII established a 
Clinical Review Committee (CRC). The CRC consisted of two dysmorphologists and a 
clinical psychologist that reviewed all cases classified as confirmed or probable by the 
algorithm.
Prior to cases being reviewed by the CRC, designated individuals at each surveillance site 
performed quality checks for completeness and accuracy of the abstracted information. This 
process also provided quality control of the computerized algorithm. Within each site, local 
review was conducted on records that the computer algorithm had classified as either 
probable or confirmed. Sites also reviewed other cases that had confirmation of only one 
facial feature or that were classified by the algorithm as probable, but lacked confirmation of 
CNS to assure possible cases were not missed.
A pooled database of de-identified cases from all surveillance sites identified from local 
review as eligible for clinical review was created and distributed to all CRC members for 
review. Each member independently reviewed and evaluated the abstracted information for 
each child. The clinician assigned a case status, based on the available information, and this 
assignment was recorded in the surveillance database. A report containing case status 
assigned by each clinician was distributed to all sites.
If all three CRC members agreed on case status, the case underwent no additional review. If 
there was disagreement among the three CRC members, the case was reviewed during a 
conference call of the CRC. After discussion of each case, if CRC members were able to 
agree on a case status, that status was assigned. Occasionally, the CRC reached a conclusion 
that additional information was needed in order to arrive at consensus. In these cases an 
effort was made to ascertain additional information, and the case was reviewed again by the 
CRC during the next month’s conference call. If CRC members disagreed about case status 
and no more information was available, the case status assignment defaulted to the lowest 
level of certainty. For example, if there was disagreement between categorizing the case as 
confirmed or probable, the case would be assigned to the probable category.
Final Case Categorization—Every child suspected of having FAS was screened for 
inclusion in FASSNetII and was classified into one of six categories. The first three 
categories included those who did not meet the inclusion criteria: children who did not have 
a birth year in 2001-2003; children who died prior to 2010; and children who did not meet 
the residency requirement. Category four included children who did not meet the case 
definition by algorithm and for which all sources of data for abstraction were exhausted. 
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Categories five and six were for cases that met the case definition. Category five included 
any child that was considered a confirmed or probable case by the computer algorithm, but 
was determined to be “not a FAS case” by the CRC. Category six included confirmed and 
probable cases that met the case definition by both the computer algorithm and the CRC.
Data Quality
Several measures were employed to maintain data quality and the consistency of data 
collection among sites. Data managers regularly reviewed the abstracted data for 
completeness and accuracy. The database application used for data collection at all sites was 
programmed with automated consistency and range check for selected variables.
Standard data abstraction procedures and an abstraction manual were developed with 
representation from all sites and CDC. During the first year of the project, abstractors 
participated in 12 hours of training. To facilitate reliability across sites, abstractors met 
monthly via conference call to review de-identified records and discuss issues encountered 
by the abstractors. Issues not addressed in the abstractors’ manual were resolved by 
consensus of the Principal Investigators and/or study clinicians. In addition, during years 
two and three of the project two quality-control exercises were completed to assess inter-
abstractor agreement on key data elements relevant to the case definition. Adjustments were 
made to the protocol when discrepancies were found, and additional training was provided 
to promote consistency in future data abstractions.
DISCUSSION
Surveillance of FAS is an important public health activity that will bring attention to the 
burden of this preventable life-long disability. Compared to other methodologies such as 
clinic-based studies, records-based systems like FASSNetII are less expensive (May et al., 
2009) and have the potential for long-term sustainability. In addition, the methodology used 
by FASSNetII can be integrated with existing birth defects or developmental disabilities 
monitoring programs and allows access to additional data to identify potential risk factors 
for both mother and child outcomes.
FASSNetII modified the surveillance methodology of FASSNet in three important ways: 1) 
estimation of a period prevalence rather than birth prevalence to address a highly mobile 
target population; 2) identification of school-age children to better document the CNS 
abnormalities that are not apparent at birth or during infancy; and 3) implementation of a 
clinical review of abstracted data of probable and confirmed cases to review and classify 
cases in more depth than is possible through a computerized, algorithm-based process.
One strength of FASSNetII was its use of multiple data sources to gather the diagnostic 
information needed to meet the surveillance case definition. Multiple sources were 
particularly important since children with FAS are often evaluated by a multidisciplinary 
team of experts (e.g., geneticist, developmental psychologist) or even a series of specialists. 
Further, some aspects of the case definition manifest for different children at a variety of 
developmental stages. For example, growth deficiencies and facial features are typically 
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apparent at birth or during infancy, but some CNS functional abnormalities do not emerge 
until later in the preschool or school age years.
A second strength of FASSNetII was that it provided an estimate of the period prevalence 
for school-age children rather than birth prevalence. A period prevalence is more useful for 
predicting the service needs of children with FAS since many functional disabilities emerge 
later in development, and adopted children could be included in the prevalence estimate. It 
allows for migration of families in and out of the catchment area as well as the capture of 
children in foster, adoptive or other out of home care situations. In addition, surveillance of 
FAS in older children provided an opportunity to better identify and describe a greater range 
of CNS abnormalities associated with FAS.
A final strength of FASSNetII was the inclusion of a clinical review component into the 
surveillance system. This provided an opportunity to assess aspects of previous public health 
surveillance efforts for FAS, especially FASSNet, which was exclusively a records-based 
system. Use of a clinical review component has proven effective in surveillance programs 
for other conditions such as autism spectrum disorders (Rice et al., 2007) and Duchenne and 
Becker muscular dystrophy (Miller et al., 2006) and could have important implications for 
future FAS surveillance efforts.
Public health surveillance for FAS has several inherent challenges which created limitations 
for FASSNetII. First, FASSNetII was limited in its ability to assess and ensure the 
completeness of case ascertainment. Its quality assurance and control procedures helped to 
ensure that the abstractions of a given case were as complete as possible, yet there were no 
procedures in place to ensure that every child with FAS was captured by the surveillance 
system, nor any gold standard against which the surveillance system could be measured. 
Second, FASSNetII was limited by its data sources. It largely relied on medical records data, 
which could be incomplete. This is evidenced by a recent study by Hansen et al. (2014) that 
used electronic health records and the FASSNet case definition to examine prevalence of 
children with features of FAS in a managed healthcare group and found documentation of 
the characteristic facial features of FAS lacking. Third, FASSNetII did not implement a 
standardized clinical evaluation for every child suspected with FAS; it relied on 
documentation provided by a wide array of community providers, with variable training and 
experience in the assessment of the condition. Fourth, because children with FAS can be 
disproportionately in the foster care system and/or living with adoptive families, it was 
challenging to identify these children and to obtain some types of information, especially 
prenatal alcohol exposure, biological parent’s demographic information, and/or the child’s 
legal address in 2010 to ensure that the criterion for residency was met. Finally, FASSNetII 
relied on data sources that were primarily from inpatient healthcare facilities. The sites were 
not able to consistently access outpatient records, behavioral health records, or school 
records. Therefore, the FAS prevalence calculable through FASSNetII data is that of the 
population identified through an encounter with the healthcare system. It represents the 
subpopulation of children with access to specialty care such as genetics or multi-disciplinary 
developmental clinics. The proportion of children with FAS who do not interact with the 
healthcare system in the United States is not known.
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FAS surveillance is an important public health activity for monitoring the effects of prenatal 
alcohol exposure as well as describing the public health burden of this disorder. Although 
records-based systems such as FASSNetII generate lower estimates of FAS prevalence than 
clinic-based studies and active in-school systems (May et al., 2009), its multiple-source 
methodology represents an important component of a sustainable surveillance system for 
FAS. Coordinated public health activities that emphasize the importance of identifying and 
diagnosing children with FAS or any of the FASDs to clinical care providers will help 
harmonize efforts across these different approaches.
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• Short palpebral fissures
• abnormal philtrum
• thin upper lip
At least one structural or
functional anomaly
STRUCTURAL
Head circumference ≤ 10th
centile at birth or any age
   Or
FUNCTIONAL
Standardized measure of
functioning in at least 2 of 9
domains ≥1 standard deviations
below the mean or diagnosis of
developmental delay by a
qualified examiner
   Or
Standardized measure of IQ ≥ 2
standard deviations below the
mean on a standardized test or
diagnosis of intellectual
disability by a qualified
examiner
   Or
ADD or ADHD diagnosed by a
qualified evaluator
Growth delay










Weight or height ≤
10th centile for age
  Or











Must meet either CNS or GROWTH criteria as
outlined in the CONFIRMED phe
Suspect All children referred into the surveillance system.
FAS – fetal alcohol syndrome; IQ – intelligence quotient; ADD – attention deficit disorder; ADHD – attention deficit hyperactivity disorder
*
Documentation in any abstracted record of maternal alcohol use during the index pregnancy.
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